Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of the Effect of Differing Platelet Transfusion Times in Neonates
The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns
Status: Archived
801
mi
from
Atlanta, GA
Study of the Effect of Differing Platelet Transfusion Times in Neonates
The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns
Status: Archived
Updated: 1/1/1970
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
801
mi
from
Atlanta, GA
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
1112
mi
from
Tampa, FL
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
1151
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
1151
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
1162
mi
from
Pasadena, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
1162
mi
from
Pasadena, CA
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
515
mi
from
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
574
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Children's Doctor
574
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
801
mi
from
Atlanta, GA
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Emory University
801
mi
from
Atlanta, GA
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
414
mi
from
St. Louis, MO
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Updated: 1/1/1970
Barnes Jewish Hospital - Washington University
414
mi
from
St. Louis, MO
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
1152
mi
from
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1152
mi
from
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
803
mi
from
Egleston, GA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
803
mi
from
Egleston, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
803
mi
from
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840003
803
mi
from
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
1289
mi
from
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840002
1289
mi
from
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
572
mi
from
Houston, TX
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840001
572
mi
from
Houston, TX
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
1341
mi
from
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
1341
mi
from
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
1168
mi
from
Los Angeles, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St. Vincent's Hospital
1168
mi
from
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
1171
mi
from
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
UCLA Orthodpedic Hospital
1171
mi
from
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
1154
mi
from
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Uc Irvine Medical Center
1154
mi
from
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
436
mi
from
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
436
mi
from
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
1125
mi
from
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
1125
mi
from
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
608
mi
from
Chicago, IL
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
608
mi
from
Chicago, IL
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
1263
mi
from
New Brunswick, NJ
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
632
mi
from
Milwaukee, WI
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
BloodCenter of Wisconsin
632
mi
from
Milwaukee, WI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
1318
mi
from
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1318
mi
from
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
1444
mi
from
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1444
mi
from
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
808
mi
from
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
808
mi
from
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
211
mi
from
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
211
mi
from
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
1290
mi
from
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1290
mi
from
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
895
mi
from
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
895
mi
from
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
349
mi
from
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
349
mi
from
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
1410
mi
from
Seattle, WA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1410
mi
from
Seattle, WA
734
mi
from
Mobile, AL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Cancer Center at Providence Hospital
734
mi
from
Mobile, AL
1380
mi
from
Portland, OR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Portland Cancer Center
1380
mi
from
Portland, OR
253
mi
from
Ft. Smith, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
253
mi
from
Ft. Smith, AR
369
mi
from
Little Rock, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
369
mi
from
Little Rock, AR
1330
mi
from
Berkeley, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Alta Bates Comprehensive Cancer Center
1330
mi
from
Berkeley, CA
1171
mi
from
Burbank, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Saint-Joseph Medical Center
1171
mi
from
Burbank, CA
1338
mi
from
Burlingame, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Peninsula Medical Center
1338
mi
from
Burlingame, CA
1283
mi
from
Marysville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
1283
mi
from
Marysville, CA
1269
mi
from
Roseville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center at Roseville Medical Center
1269
mi
from
Roseville, CA
1282
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center
1282
mi
from
Sacramento, CA
1281
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
1281
mi
from
Sacramento, CA
1341
mi
from
San Francisco, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center - California Campus
1341
mi
from
San Francisco, CA
1344
mi
from
San Rafael, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Health - Western Division Cancer Research Group
1344
mi
from
San Rafael, CA
1327
mi
from
Vallejo, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Solano Medical Center
1327
mi
from
Vallejo, CA
722
mi
from
Chattanooga, TN
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Memorial Hospital
722
mi
from
Chattanooga, TN
434
mi
from
Fort Collins, CO
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Poudre Valley Hospital
434
mi
from
Fort Collins, CO
1358
mi
from
Hartford, CT
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
1358
mi
from
Hartford, CT
1142
mi
from
Orlando, FL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
1142
mi
from
Orlando, FL
884
mi
from
Albany, GA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Phoebe Putney Memorial Hospital
884
mi
from
Albany, GA
798
mi
from
Atlanta, GA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
CCOP - Atlanta Regional
798
mi
from
Atlanta, GA